Sign in

CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company

Ernexa Therapeutics Inc.

Sign in to watch
Ticker
ERNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
311103425
Phone
(617) 798-6700
Business address
1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
Former names
Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Securities

  • ERNA Common Stock Nasdaq
  • ERNAW Warrants Nasdaq
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Open-market buy 10% owner bought 75,341 shares at $0.15 ($10,985)
  4. 4/A Open-market buy 10% owner bought 644,500 shares at an average $0.13 ($83,368)
  5. 4 Open-market buy 10% owner bought 35,000 shares at $0.14 ($4,883)
  6. 4 Open-market buy 10% owner bought 525,800 shares at an average $0.13 ($66,809)
  7. 4 Open-market buy 10% owner bought 45,965 shares at an average $0.13 ($6,143)
  8. SC 13D/A Stake Beneficial Ownership Report
  9. 4 Open-market buy Director bought 10,000 shares at $0.12 ($1,200)
  10. 4 Open-market buy 10% owner bought 351,000 shares at $0.12 ($42,120)
  11. SC 13D/A Stake Beneficial Ownership Report
  12. 4 Open-market buy Director bought 10,000 shares at $0.11 ($1,100)
  13. 4 Open-market buy Director bought 1,250,000 shares at $0.13 ($162,500)
  14. 4 Open-market buy 10% owner bought 275,800 shares at an average $0.12 ($32,601)
  15. 4 Open-market buy Director bought 20,000 shares at an average $0.12 ($2,400)
  16. 4 Open-market buy Director bought 10,000 shares at $0.14 ($1,400)
  17. 8-K Event Material agreement · Executive or director change
  18. 4 Open-market buy Director bought 20,000 shares at an average $0.14 ($2,750)
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 56 of 77 · 1,525 filings